WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first

Manufacturing

ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres

MedDevice Startups Staff · 4 days ago · 2 min read · Via ABK Biomedical (PR Newswire)

ABK Biomedical has started building a GMP plant in Ashland, Missouri, at Cartwright Business Park. The site is for commercial-scale production of Eye90 microspheres, the company's imageable yttrium-90 radioembolization device for hypervascular tumors. Construction finishes in 2027 and commissioning follows in 2028.

ABK is based in Halifax, Nova Scotia, with a second office in Orange County, California. It named the University of Missouri Research Reactor as a partner on the project, alongside COR Development and Coil Construction. The company has not disclosed the capital cost or a headcount for the site.

Eye90 is still investigational, so ABK is committing to capacity well before it has a US authorization to sell into. That order of operations is normal for a Y90 device, where isotope supply and plant qualification take longer than a submission review, and siting next to a research reactor is the part that is hard to redo later.

Questions & Answers

Where is ABK Biomedical building its Eye90 microspheres plant?

ABK Biomedical broke ground on October 2, 2026 at Cartwright Business Park in Ashland, Missouri. The GMP facility is for commercial-scale production of Eye90 microspheres, with construction finishing in 2027 and commissioning in 2028.

What are ABK Biomedical's Eye90 microspheres?

Eye90 microspheres are ABK Biomedical's yttrium-90 radioembolization device for hypervascular tumors, built on a glass composition that stays visible during the procedure. ABK describes the product as investigational and not approved for use outside authorized clinical trials.

Where is ABK Biomedical based?

ABK Biomedical is headquartered in Halifax, Nova Scotia, and keeps a second office in Orange County, California. Its commercial manufacturing plant is going up in Ashland, Missouri.

← Back to Startups